Glecaprevir/Pibrentasvir: The First 8-Week, Pangenotypic HCV Treatment Regimen for Patients 12 Years of Age and Older.
Conclusions: With HCV infection rates remaining elevated, it is important to have safe and efficacious treatment options. Glecaprevir/pibrentasvir is a safe and efficacious guideline-recommended, 8-week treatment for HCV in several patient populations, with these populations likely growing in the near future given ongoing and future studies.
PMID: 31537106 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - Category: Drugs & Pharmacology Authors: Huff J, Andersen R Tags: Ann Pharmacother Source Type: research
More News: Chemistry | Cirrhosis | Clinical Trials | Drugs & Pharmacology | Hepatitis | Hepatitis C | Kidney Transplant | Kidney Transplantation | Liver | Liver Transplant | Study | Transplant Surgery | Transplants | Urology & Nephrology | Virology